Header Logo

VINCENT H. TAM

TitleProfessor
InstitutionUniversity of Houston
DepartmentPharmacy Practice and Translational Research
AddressHealth 2 4849 Calhoun Road, Room 4041
Houston, TX 77204-5039
Houston TX 77204-5039
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01AI140287     (TAM, VINCENT H)Aug 15, 2018 - Jun 30, 2029
    NIH
    Personalized Antimicrobial Combinations to Combat Resistance
    Role: Principal Investigator
    R56AI111793     (TAM, VINCENT H)Aug 1, 2014 - Jul 31, 2016
    NIH
    Optimized Antimicrobial Combinations to Suppress Resistance
    Role: Principal Investigator
    R15AI089671     (TAM, VINCENT H)Mar 29, 2010 - Sep 28, 2013
    NIH
    Clinical Pharmacology of Polymyxin B
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Carvajal LP, Rincon S, Gomez Villegas SI, Matiz-Gonzalez JM, Ordo?ez K, Santamaria A, Ospina Navarro L, Beltran J, Guevara F, Mendez YR, Salcedo S, Porras A, Valencia-Moreno A, Greenia H, Deyanov A, Baptista R, Tam VH, Panesso D, Tran TT, Miller WR, Arias CA, Reyes J. Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 Nov 06; 68(11):e0089824. PMID: 39345182; PMCID: PMC11539226.
      Citations:    Fields:    
    2. Truong M, Tolleson S, Ordonez ND, Tam VH, Truong M, Tolleson S, Ordonez ND, Tam VH. Correlating Advanced Pharmacy Practice Experience Exam Scores and Pharmacist Licensure Status in a Single Program. Am J Pharm Educ. 2024 Sep; 88(9):101255. PMID: 39089630.
      Citations:    Fields:    Translation:Humans
    3. Carvajal LP, Rincon S, Gomez-Villegas SI, Matiz-Gonz?lez JM, Ordo?ez K, Santamaria A, Ospina-Navarro L, Beltran J, Guevara F, Mendez YR, Salcedo S, Porras A, Valencia-Moreno A, Grennia H, Deyanov A, Baptista R, Tam VH, Panesso D, Tran TT, Miller WR, Arias CA, Reyes J. Prevalence of the Cefazolin Inoculum Effect (CzIE) in Nasal Colonizing Methicillin-Susceptible Staphylococcus aureus in Patients from Intensive Care Units in Colombia and Use of a Modified Rapid Nitrocefin Test for Detection. medRxiv. 2024 Jul 11. PMID: 39040169; PMCID: PMC11261917.
      Citations:    
    4. Pouya N, Smith JE, Hudson CS, Teran NS, Tam VH, Pouya N, Smith JE, Hudson CS, Teran NS, Tam VH. In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255. PMID: 38996872.
      Citations:    Fields:    Translation:HumansCells
    5. Hudson CS, Roy A, Li Q, Joshi AS, Yin T, Kumar A, Sheikh-Hamad D, Tam VH, Hudson CS, Roy A, Li Q, Joshi AS, Yin T, Kumar A, Sheikh-Hamad D, Tam VH. Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury. Am J Physiol Renal Physiol. 2024 Jul 01; 327(1):F137-F145. PMID: 38779756.
      Citations:    Fields:    Translation:AnimalsCells
    6. Eales BM, Smith JE, Pouya N, Teran NS, Miller WR, Tam VH. Alternative iron-depleted media for cefiderocol susceptibility testing. Int J Antimicrob Agents. 2024 Jul; 64(1):107193. PMID: 38723696.
      Citations:    Fields:    Translation:Humans
    7. Shen X, Kellamis C, Tam V, Sinclair N, Wainright J, Savinell R. An All-Soluble Fe/Mn-Based Alkaline Redox Flow Battery System. ACS Appl Mater Interfaces. 2024 Apr 17; 16(15):18686-18692. PMID: 38573309.
      Citations:    Fields:    
    8. Teran NS, Vuong L, Phe K, Lasco TM, Miller WR, Tam VH. Comparison of cefiderocol in-vitro susceptibility testing modalities. J Glob Antimicrob Resist. 2024 Jun; 37:100-101. PMID: 38552875; PMCID: PMC11344908.
      Citations: 1     Fields:    Translation:Humans
    9. Teran N, Egge SL, Phe K, Baptista RP, Tam VH, Miller WR. The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 Jan 10; 68(1):e0100923. PMID: 38063509; PMCID: PMC10777823.
      Citations: 1     Fields:    Translation:HumansCells
    10. Hudson CS, Smith JE, Eales BM, Kajiji S, Liu X, Truong LD, Tam VH. Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model. J Antimicrob Chemother. 2023 10 03; 78(10):2435-2441. PMID: 37563789.
      Citations:    Fields:    Translation:HumansAnimals
    11. Hudson CS, Smith JE, Eales BM, Nikolaou M, Tam VH. In vitro model to simulate multiple drugs with distinct elimination half-lives. Int J Antimicrob Agents. 2023 Oct; 62(4):106924. PMID: 37433386; PMCID: PMC11344907.
      Citations:    Fields:    Translation:Humans
    12. Nikolaou M, Tam VH. Rapid In Vitro Assessment of Antimicrobial Drug Effect Bridging Clinically Relevant Pharmacokinetics: A Comprehensive Methodology. Pharmaceutics. 2023 Jun 07; 15(6). PMID: 37376120; PMCID: PMC10305065.
      Citations:    
    13. Gatti M, Tam VH, Gaibani P, Cojutti PG, Viale P, Pea F. A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760. PMID: 36804371; PMCID: PMC10498894.
      Citations: 1     Fields:    Translation:Humans
    14. Eales BM, Bai B, Merlau PR, Tam VH. Growth of Acinetobacter baumannii impacted by iron chelation. Lett Appl Microbiol. 2023 Feb 16; 76(2). PMID: 36731874; PMCID: PMC9990167.
      Citations:    Fields:    Translation:HumansAnimalsCells
    15. Chua HC, Tam VH. Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools. Open Forum Infect Dis. 2022 Dec; 9(12):ofac626. PMID: 36540388; PMCID: PMC9757694.
      Citations:    
    16. Bai B, Eales BM, Huang W, Ledesma KR, Merlau PR, Li G, Yu Z, Tam VH. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927. PMID: 36308002; PMCID: PMC9621070.
      Citations: 1     Fields:    Translation:HumansCells
    17. Tu Y, Wang L, Rong Y, Tam V, Yin T, Gao S, Singh R, Hu M. Correction: Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. Elife. 2022 Nov 02; 11. PMID: 36322455; PMCID: PMC9629825.
      Citations:    Fields:    
    18. Kesisoglou I, Eales BM, Merlau PR, Tam VH, Nikolaou M. Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Comput Methods Programs Biomed. 2022 Dec; 227:107212. PMID: 36335752; PMCID: PMC10225978.
      Citations: 1     Fields:    Translation:Humans
    19. Tam VH, Merlau PR, Hudson CS, Kline EG, Eales BM, Smith J, Sofjan AK, Shields RK. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137. PMID: 36031868; PMCID: PMC10205629.
      Citations:    
    20. Bai B, Chen C, Zhao Y, Xu G, Yu Z, Tam VH, Wen Z. In vitro activity of tigecycline and proteomic analysis of tigecycline adaptation strategies in clinical Enterococcus faecalis isolates from China. J Glob Antimicrob Resist. 2022 09; 30:66-74. PMID: 35508286.
      Citations:    Fields:    
    21. Zidaru A, Phe K, Lasco TM, Tam VH. An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Am J Health Syst Pharm. 2022 03 07; 79(6):467-471. PMID: 34849535.
      Citations:    Fields:    Translation:Humans
    22. Garcia CR, Malik MH, Biswas S, Tam VH, Rumbaugh KP, Li W, Liu X. Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils. Biomater Sci. 2022 Feb 01; 10(3):633-653. PMID: 34994371.
      Citations: 1     Fields:    
    23. Kesisoglou I, Tam VH, Tomaras AP, Nikolaou M. Discerning in vitro pharmacodynamics from OD measurements: A model-based approach. Comput Chem Eng. 2022 Feb; 158. PMID: 35250117; PMCID: PMC8896896.
      Citations:    
    24. Zidaru A, Sofjan AK, Devarajan SR, Tam VH. Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection. J Glob Antimicrob Resist. 2022 06; 29:551-552. PMID: 34922054.
      Citations:    Fields:    Translation:HumansCells
    25. Tam VH, Hudson CS, Merlau PR, Shields RK. Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. J Chemother. 2022 09; 34(5):345-346. PMID: 34806561; PMCID: PMC9124231.
      Citations:    Fields:    
    26. Eales BM, Tam VH. Case Commentary: Novel Therapy for Multidrug-Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2022 01 18; 66(1):e0199621. PMID: 34694874; PMCID: PMC8765303.
      Citations:    Fields:    Translation:HumansCells
    27. Eales BM, Hudson CS, Kesisoglou I, Wang W, Nikolaou M, Tam VH. Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model. Antibiotics (Basel). 2021 Oct 16; 10(10). PMID: 34680836; PMCID: PMC8532833.
      Citations:    
    28. Kesisoglou I, Eales BM, Ledesma KR, Merlau PR, Tam VH, Wang W, Nikolaou M. SIMULTANEOUS IN VITRO SIMULATION OF MULTIPLE ANTIMICROBIAL AGENTS WITH DIFFERENT ELIMINATION HALF-LIVES IN A PRE-CLINICAL INFECTION MODEL. Comput Chem Eng. 2021 Dec; 155. PMID: 34924641; PMCID: PMC8682276.
      Citations:    
    29. Tu Y, Wang L, Rong Y, Tam V, Yin T, Gao S, Singh R, Hu M. Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. Elife. 2021 07 01; 10. PMID: 34196607; PMCID: PMC8248983.
      Citations:    Fields:    Translation:Animals
    30. Khan S, Phe K, Tam VH. Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597. PMID: 33645440.
      Citations:    Fields:    Translation:Humans
    31. Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L. Erratum for Yahav et al., "New ?-Lactam-?-Lactamase Inhibitor Combinations". Clin Microbiol Rev. 2021 Mar 17; 34(2). PMID: 33504504; PMCID: PMC7849239.
      Citations: 4     Fields:    
    32. Tam VH, Abodakpi H, Wang W, Ledesma KR, Merlau PR, Chan K, Altman R, Tran TT, Nikolaou M, Sofjan AK. Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183. PMID: 33035321; PMCID: PMC7729384.
      Citations: 3     Fields:    Translation:Cells
    33. Lodise TP, Gallagher JC, Tam VH, Mohr JF, Ferry T, Forestier E, Goutelle S, Roubaud-Baudron C. Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. Front Med (Lausanne). 2020; 7:585658. PMID: 33425938; PMCID: PMC7785854.
      Citations:    
    34. Ng TM, Heng ST, Oon J, Chan M, Tam VH. Validation of Vancomycin Dosing Guidance During Transition of Care. J Clin Pharmacol. 2021 06; 61(6):806-809. PMID: 33258161.
      Citations:    Fields:    Translation:Humans
    35. Tam VH, Lee LS, Ng TM, Lim TP, Cherng BPZ, Adewusi H, Hee KH, Ding Y, Chung SJ, Ling LM, Chlebicki P, Kwa ALH, Lye DC. Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures. Microorganisms. 2020 Nov 18; 8(11). PMID: 33217914; PMCID: PMC7698783.
      Citations: 2     
    36. Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L. New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1). PMID: 33177185; PMCID: PMC7667665.
      Citations: 58     Fields:    Translation:Cells
    37. Zidaru A, Eales BM, Wang W, Merlau PR, Lasco TM, Sofjan AK, Tam VH. MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates. J Glob Antimicrob Resist. 2020 12; 23:385-387. PMID: 33166758; PMCID: PMC7770049.
      Citations:    Fields:    Translation:HumansCells
    38. Dhaese S, Heffernan A, Liu D, Abdul-Aziz MH, Stove V, Tam VH, Lipman J, Roberts JA, De Waele JJ. Prolonged Versus Intermittent Infusion of ?-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clin Pharmacokinet. 2020 10; 59(10):1237-1250. PMID: 32710435.
      Citations: 6     Fields:    Translation:Humans
    39. Chan K, Ledesma KR, Wang W, Tam VH. Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. Antimicrob Agents Chemother. 2020 08 20; 64(9). PMID: 32571819; PMCID: PMC7449196.
      Citations: 1     Fields:    Translation:Animals
    40. Phe K, Heil EL, Tam VH. Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review. J Infect Dis. 2020 07 21; 222(Suppl 2):S132-S141. PMID: 32691832; PMCID: PMC7372216.
      Citations: 7     Fields:    Translation:Humans
    41. Chan K, Wang W, Ledesma KR, Yin T, Tam VH. A robust LC-MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies. Bioanalysis. 2020 Apr; 12(7):445-454. PMID: 32343148; PMCID: PMC7270885.
      Citations: 3     Fields:    Translation:Humans
    42. Tam VH, Cohen DN, Ledesma KR, Guillory B, Chan K, Garey KW. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 02 21; 64(3). PMID: 31871078; PMCID: PMC7038272.
      Citations: 1     Fields:    Translation:Animals
    43. Xie LX, Zhou J, Ledesma KR, Merlau PR, Tam VH. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254. PMID: 31770603.
      Citations:    Fields:    Translation:AnimalsCells
    44. Skoglund E, Abodakpi H, Dinh AQ, Miller WR, Munita JM, Tam VH, Tran TT, Rios R, Diaz L, De La Cadena E, Ardila J, Arias CA. Corrigendum to "In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways". Case Rep Infect Dis. 2019; 2019:8314349. PMID: 31565449; PMCID: PMC6745093.
      Citations:    
    45. Abodakpi H, Wanger A, Tam VH. What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on ?-Lactam/?-Lactamase Inhibitor Combinations. Clin Lab Med. 2019 09; 39(3):473-485. PMID: 31383269; PMCID: PMC6686870.
      Citations: 6     Fields:    Translation:HumansCells
    46. Quoc Hoang TA, Tam V, Thang HV. Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease. Med J Malaysia. 2019 06; 74(3):209-214. PMID: 31256175.
      Citations: 1     Fields:    Translation:Humans
    47. Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL, Bulitta JB. Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents Chemother. 2019 05; 63(5). PMID: 30833428; PMCID: PMC6496039.
      Citations: 50     Fields:    Translation:HumansAnimals
    48. Abodakpi H, Chang KT, Gao S, Tam VH, S?nchez-D?az AM, Cant?n R. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2). PMID: 30530606; PMCID: PMC6355564.
      Citations: 4     Fields:    Translation:HumansCells
    49. Abodakpi H, Chang KT, Zhou J, Byerly C, Tam VH. A novel framework to compare the effectiveness of ?-lactamase inhibitors against extended-spectrum ?-lactamase-producing Enterobacteriaceae. Clin Microbiol Infect. 2019 Sep; 25(9):1154.e9-1154.e14. PMID: 30664934; PMCID: PMC6639165.
      Citations: 5     Fields:    Translation:HumansCells
    50. Pogue JM, Tam VH. Toxicity in Patients. Adv Exp Med Biol. 2019; 1145:289-304. PMID: 31364083.
      Citations: 4     Fields:    Translation:Humans
    51. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, Kaye D, Mouton JW, Tam VH, Thamlikitkul V, Wunderink RG, Li J, Nation RL, Kaye KS. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 01; 39(1):10-39. PMID: 30710469; PMCID: PMC7437259.
      Citations: 164     Fields:    Translation:Humans
    52. Skoglund E, Abodakpi H, Dinh AQ, Miller WR, Munita JM, Tam VH, Tran TT, Rios R, Diaz L, De La Cadena E, Ardila J, Arias CA. In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways. Case Rep Infect Dis. 2018; 2018:9095203. PMID: 30675406; PMCID: PMC6323425.
      Citations: 13     
    53. Phe K, Bowers DR, Babic JT, Tam VH. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348. PMID: 30522794.
      Citations: 1     Fields:    Translation:Humans
    54. Tam VH, Ledesma KR, Lewis RE, P?rez C. Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiol Immunol. 2018 Apr; 62(4):291-294. PMID: 29418013.
      Citations: 4     Fields:    Translation:AnimalsCells
    55. Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS, Tam VH. Population Pharmacokinetics of Polymyxin B. Clin Pharmacol Ther. 2018 09; 104(3):534-538. PMID: 29238962.
      Citations: 17     Fields:    Translation:Humans
    56. Abodakpi H, Chang KT, Lasco TM, Chan K, Sofjan AK, Tam VH, S?nchez D?az AM, Cant?n R. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother. 2018 Apr; 30(2):115-119. PMID: 29125052.
      Citations: 4     Fields:    Translation:HumansCells
    57. Skoglund E, Ledesma KR, Lasco TM, Tam VH. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 12; 11:154-155. PMID: 29101084.
      Citations: 1     Fields:    Translation:HumansCells
    58. Babic JT, Manchandani P, Ledesma KR, Tam VH. Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 11; 61(11). PMID: 28848003; PMCID: PMC5655104.
      Citations: 3     Fields:    Translation:Humans
    59. Grossman TH, Anderson MS, Christ D, Gooldy M, Henning LN, Heine HS, Kindt MV, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH, Sutcliffe JA. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8). PMID: 28559261; PMCID: PMC5527625.
      Citations: 4     Fields:    Translation:AnimalsCells
    60. Singh KV, Tran TT, Tam VH, Arias CA, Murray BE, Nannini EC. Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017 07; 61(7). PMID: 28483961; PMCID: PMC5487651.
      Citations: 9     Fields:    Translation:AnimalsCells
    61. Zhou J, Tran BT, Tam VH. The complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 06 01; 72(6):1632-1634. PMID: 28333250.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    62. Tran TT, Tam VH, Murray BE, Arias CA, Singh KV. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6). PMID: 28320712; PMCID: PMC5444151.
      Citations: 1     Fields:    Translation:AnimalsCells
    63. Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, Van Bambeke F, S?nchez-D?az AM, Zamorano L, Oliver A, Cant?n R. Determining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 05 01; 72(5):1421-1428. PMID: 28158470.
      Citations: 27     Fields:    Translation:HumansCells
    64. Zhou J, Ledesma KR, Chang KT, Abodakpi H, Gao S, Tam VH. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5). PMID: 28264853; PMCID: PMC5404596.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    65. Felton TW, Nielsen EI, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA, Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Phar, T?ngd?n T, Ramos Mart?n V, Marchand S, Br?ggemann RJ. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017 Jul; 43(7):1021-1032. PMID: 28409203.
      Citations: 38     Fields:    Translation:HumansAnimals
    66. Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VH. Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity. Antimicrob Agents Chemother. 2017 04; 61(4). PMID: 28096166; PMCID: PMC5365704.
      Citations: 10     Fields:    Translation:Animals
    67. Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VH. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. Antimicrob Agents Chemother. 2017 01; 61(1). PMID: 27799209; PMCID: PMC5192162.
      Citations: 20     Fields:    Translation:Humans
    68. Manchandani P, Dubrovskaya Y, Gao S, Tam VH. Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. Antimicrob Agents Chemother. 2016 11; 60(11):6980-6982. PMID: 27697755; PMCID: PMC5075123.
      Citations: 9     Fields:    Translation:HumansAnimals
    69. Phe K, Shields RK, Tverdek FP, Aitken SL, Guervil DJ, Lam WM, Musgrove RJ, Luce AM, Tam VH. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. J Antimicrob Chemother. 2016 12; 71(12):3585-3587. PMID: 27543655; PMCID: PMC6296320.
      Citations: 6     Fields:    Translation:Humans
    70. Trad MA, Zhong LH, Llorin RM, Tan SY, Chan M, Archuleta S, Sulaiman Z, Tam VH, Lye DC, Fisher DA. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017 Feb; 29(1):25-29. PMID: 27239695.
      Citations: 6     Fields:    Translation:Humans
    71. Cao H, Phe K, Laine GA, Russo HR, Putney KS, Tam VH. An institutional review of antimicrobial stewardship interventions. J Glob Antimicrob Resist. 2016 09; 6:75-77. PMID: 27530844.
      Citations: 2     Fields:    Translation:Humans
    72. Shariff M, Quik M, Holgate J, Morgan M, Patkar OL, Tam V, Belmer A, Bartlett SE. Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake. PLoS One. 2016; 11(3):e0150270. PMID: 27028298; PMCID: PMC4814119.
      Citations: 15     Fields:    Translation:Animals
    73. Cheung CL, Sing CW, Tang CS, Cheng VK, Pirmohamed M, Choi CH, Hung CS, Lau EY, Lee KF, Mak MW, Leung JY, Wong TW, Ho AY, Chan KW, Hung V, Tam V, Siu SC, Pang HK, Wat WZ, Lee HH, Chung CT, Hue RS, Sham PC, Cheung BM, Wong IC, Tan KC, Kung A. HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis. Clin Pharmacol Ther. 2016 May; 99(5):555-61. PMID: 26599303.
      Citations: 22     Fields:    Translation:Humans
    74. Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VH. Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2016 Feb; 60(2):1029-34. PMID: 26643340; PMCID: PMC4750689.
      Citations: 19     Fields:    Translation:Animals
    75. Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. J Antimicrob Chemother. 2016 Mar; 71(3):727-30. PMID: 26612873.
      Citations: 2     Fields:    Translation:Humans
    76. Patel TS, Cottreau JM, Hirsch EB, Tam VH. Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8. PMID: 26639227.
      Citations: 1     Fields:    Translation:HumansCells
    77. Zhang D, Wu L, Chow DS, Tam VH, Rios DR. Quantitative determination of dopamine in human plasma by a highly sensitive LC-MS/MS assay: Application in preterm neonates. J Pharm Biomed Anal. 2016 Jan 05; 117:227-31. PMID: 26372947.
      Citations: 7     Fields:    Translation:Humans
    78. Abodakpi H, Gohlke J, Chang KT, Chow DS, Tam VH. Analytical and functional determination of polymyxin B protein binding in serum. Antimicrob Agents Chemother. 2015 Nov; 59(11):7121-3. PMID: 26324262; PMCID: PMC4604353.
      Citations: 3     Fields:    Translation:HumansCells
    79. Bhagunde PR, Nikolaou M, Tam VH. Modeling Heterogeneous Bacterial Populations Exposed to Antibiotics: The Logistic-Dynamics Case. AIChE J. 2015 Aug; 61(8):2385-2393. PMID: 37206682; PMCID: PMC10195107.
      Citations: 2     
    80. Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD. Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother. 2015 May; 59(5):2930-3. PMID: 25712358; PMCID: PMC4394766.
      Citations: 5     Fields:    Translation:Animals
    81. Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5. PMID: 25712362; PMCID: PMC4394818.
      Citations: 25     Fields:    Translation:AnimalsCells
    82. Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother. 2015; 70(6):1903-7. PMID: 25652747.
      Citations: 22     Fields:    Translation:Humans
    83. Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, Tam VH. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4. PMID: 25665726.
      Citations: 17     Fields:    Translation:Humans
    84. Phe K, Dao D, Palmer HR, Tam VH. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1370. PMID: 25403674; PMCID: PMC4335838.
      Citations: 3     Fields:    Translation:Cells
    85. Zasowski E, Bland CM, Tam VH, Lodise TP. Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. J Antimicrob Chemother. 2015 Mar; 70(3):877-81. PMID: 25381169.
      Citations: 3     Fields:    Translation:Humans
    86. Nation RL, Li J, Cars O, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD, Couet W. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34. PMID: 25459221.
      Citations: 114     Fields:    Translation:Humans
    87. Abdelraouf K, Tam VH. Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?". Antimicrob Agents Chemother. 2014 Oct; 58(10):6339. PMID: 25225341; PMCID: PMC4187904.
      Citations: 1     Fields:    Translation:AnimalsCells
    88. Bernhardt MB, Moffett BS, Johnson M, Tam VH, Thompson P, Garey KW. Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan; 62(1):80-4. PMID: 25263332.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    89. Phe K, Johnson ML, Palmer HR, Tam VH. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014 Nov; 58(11):6946-8. PMID: 25136012; PMCID: PMC4249357.
      Citations: 10     Fields:    Translation:HumansCells
    90. Zhang D, Rios DR, Tam VH, Chow DS. Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child. J Pharm Biomed Anal. 2014 Oct; 99:67-73. PMID: 25072843.
      Citations: 3     Fields:    Translation:Humans
    91. Tan MW, Lye DC, Ng TM, Nikolaou M, Tam VH. Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2014 Sep; 58(9):5239-44. PMID: 24957824; PMCID: PMC4135838.
      Citations:    Fields:    Translation:HumansCells
    92. Zhou J, Sulaiman Z, Llorin RM, Hee KH, Lee LS, Lye DC, Fisher DA, Tam VH. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014 Sep; 69(9):2517-21. PMID: 24797063.
      Citations: 8     Fields:    Translation:Humans
    93. Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother. 2014 Jul; 58(7):4200-2. PMID: 24733472; PMCID: PMC4068554.
      Citations: 19     Fields:    Translation:AnimalsCells
    94. Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014 May; 58(5):2740-6. PMID: 24566187; PMCID: PMC3993221.
      Citations: 63     Fields:    Translation:HumansCells
    95. Hirsch EB, Chang KT, Zucchi PC, Francoeur DN, Ledesma KR, Tam VH, Lasco TM. An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother. 2014 Mar; 20(3):224-7. PMID: 24674388.
      Citations: 5     Fields:    Translation:HumansCells
    96. Ou LC, Faulkner C, Tam V, Leiter JC. Liver function in rats acclimatized to a simulated altitude of 5500 m. High Alt Med Biol. 2013 Dec; 14(4):375-82. PMID: 24377345.
      Citations: 1     Fields:    Translation:AnimalsCells
    97. Ng TM, Lye DC, Chan M, Tam VH. Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. Int J Antimicrob Agents. 2014 Feb; 43(2):197-9. PMID: 24359843.
      Citations: 1     Fields:    Translation:Humans
    98. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis. 2014 Jan; 58(1):139-41. PMID: 24107410.
      Citations: 21     Fields:    Translation:Humans
    99. He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents. 2013 Dec; 42(6):559-64. PMID: 24016799; PMCID: PMC3849129.
      Citations: 10     Fields:    Translation:AnimalsCells
    100. Bowers DR, Tam VH. Pseudomonas aeruginosa treatment and transmission reduction. Expert Rev Anti Infect Ther. 2013 Aug; 11(8):831-7. PMID: 23977938.
      Citations:    Fields:    Translation:HumansCells
    101. He J, Gao S, Hu M, Chow DS, Tam VH. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother. 2013 May; 68(5):1104-10. PMID: 23341128; PMCID: PMC3625435.
      Citations: 12     Fields:    Translation:Animals
    102. Tam VH, Hirsch EB, Lasco TM, Gentry LO, Palmer HR. Correlation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1120-2. PMID: 22764323.
      Citations: 3     Fields:    Translation:Cells
    103. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother. 2012 Sep; 56(9):4625-9. PMID: 22687519; PMCID: PMC3421883.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    104. Tran TT, Palmer HR, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose-optimization protocol. Am J Health Syst Pharm. 2012 Jun 01; 69(11):979-84. PMID: 22610031.
      Citations: 4     Fields:    Translation:Humans
    105. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7. PMID: 22526311; PMCID: PMC3393460.
      Citations: 64     Fields:    Translation:Cells
    106. Tiong CT, Chen C, Zhang SJ, Li J, Soshilov A, Denison MS, Lee LS, Tam VH, Wong SP, Xu HE, Yong EL. A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERa protein. Carcinogenesis. 2012 May; 33(5):1089-97. PMID: 22345291; PMCID: PMC3334513.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    107. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40. PMID: 22330927; PMCID: PMC3346582.
      Citations: 18     Fields:    Translation:HumansCells
    108. Singh R, Swick MC, Ledesma KR, Yang Z, Hu M, Zechiedrich L, Tam VH. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother. 2012 Apr; 56(4):1680-5. PMID: 22232279; PMCID: PMC3318314.
      Citations: 30     Fields:    Translation:Cells
    109. Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother. 2012 Apr; 67(4):928-32. PMID: 22232512.
      Citations: 15     Fields:    Translation:HumansCells
    110. Weston J, Gentry L, Salazar M, Putney K, Frost C, Tipton JA, Cottreau J, Tam VH, Garey KW, Palmer HR. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15; 68(22):2170-4. PMID: 22058103.
      Citations: 5     Fields:    Translation:Humans
    111. Hirsch EB, Cottreau JM, Chang KT, Caeiro JP, Johnson ML, Tam VH. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan; 72(1):97-102. PMID: 22056006.
      Citations: 5     Fields:    Translation:HumansCells
    112. Singh R, Tam VH. Optimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr Opin Pharmacol. 2011 Oct; 11(5):453-6. PMID: 21868287.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    113. Guo B, Abdelraouf K, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct; 55(10):4601-5. PMID: 21807974; PMCID: PMC3186951.
      Citations: 13     Fields:    Translation:AnimalsCells
    114. Tam VH, Cao H, Ledesma KR, Hu M. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother. 2011 Sep; 55(9):4490-1. PMID: 21709096; PMCID: PMC3165278.
      Citations: 14     Fields:    Translation:Cells
    115. Salvatore CM, Abdelraouf K, Hsing DD, Tam VH. Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia. Pediatr Infect Dis J. 2011 Jun; 30(6):537-9. PMID: 21164382; PMCID: PMC10278368.
      Citations: 2     Fields:    Translation:HumansCells
    116. Kwa AL, Falagas ME, Michalopoulos A, Tam VH. Benefits of aerosolized colistin for ventilator-associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis. 2011 May; 52(10):1278-9; author reply 1279-80. PMID: 21507926.
      Citations: 3     Fields:    Translation:Humans
    117. Kwa AL, Abdelraouf K, Low JG, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011 May; 52(10):1280-1. PMID: 21507928; PMCID: PMC3115279.
      Citations: 20     Fields:    Translation:Humans
    118. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH. Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother. 2011 Jun; 66(6):1311-7. PMID: 21415038.
      Citations: 23     Fields:    Translation:AnimalsCells
    119. Bhagunde P, Singh R, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design. J Antimicrob Chemother. 2011 May; 66(5):1079-86. PMID: 21393141.
      Citations: 4     Fields:    Translation:HumansCells
    120. Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VH. Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis. 2011 Feb; 69(2):234-5. PMID: 21251574.
      Citations: 5     Fields:    Translation:HumansCells
    121. Tam VH, Nikolaou M. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol. 2011 Jan 06; 7(1):e1001043. PMID: 21253559; PMCID: PMC3017105.
      Citations: 12     Fields:    
    122. Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, Dupont HL. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis. 2010 Dec 15; 51(12):1406-10. PMID: 21058913.
      Citations: 36     Fields:    Translation:HumansCells
    123. Bhagunde P, Chang KT, Singh R, Singh V, Garey KW, Nikolaou M, Tam VH. Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother. 2010 Nov; 54(11):4739-43. PMID: 20805390; PMCID: PMC2976129.
      Citations: 7     Fields:    Translation:Cells
    124. Palmer HR, Cottreau JM, Garey KW, Hirsch EB, Musick WL, Tam VH, Yeh RF, Houston Infectious Diseases Network. Significant publications on infectious diseases pharmacotherapy in 2009. Am J Health Syst Pharm. 2010 Aug; 67(15):e34-42. PMID: 20651305.
      Citations:    Fields:    Translation:Humans
    125. Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010 Aug; 10(4):441-51. PMID: 20715920; PMCID: PMC3071543.
      Citations: 122     Fields:    Translation:HumansCells
    126. Singh R, Ledesma KR, Chang KT, Tam VH. Impact of recA on levofloxacin exposure-related resistance development. Antimicrob Agents Chemother. 2010 Oct; 54(10):4262-8. PMID: 20660686; PMCID: PMC2944593.
      Citations: 11     Fields:    Translation:Cells
    127. He J, Figueroa DA, Lim TP, Chow DS, Tam VH. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25 degrees C. Am J Health Syst Pharm. 2010 Jul 15; 67(14):1191-4. PMID: 20592326.
      Citations: 5     Fields:    Translation:CellsPHPublic Health
    128. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010 Jun; 65(6):1119-25. PMID: 20378670.
      Citations: 155     Fields:    Translation:HumansCells
    129. Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis. 2010 Mar 15; 201(6):889-97. PMID: 20156065.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    130. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1160-4. PMID: 20086165; PMCID: PMC2826008.
      Citations: 43     Fields:    Translation:HumansCells
    131. Hsu LY, Tan TY, Tam VH, Kwa A, Fisher DA, Koh TH, Network for Antimicrobial Resistance Surveillance (Singapore). Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother. 2010 Mar; 54(3):1173-8. PMID: 20065055; PMCID: PMC2826017.
      Citations: 45     Fields:    Translation:HumansCells
    132. He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents. 2010 Mar; 35(3):308-10. PMID: 20045285.
      Citations: 15     Fields:    Translation:Humans
    133. Xu H, Kulkarni KH, Singh R, Yang Z, Wang SW, Tam VH, Hu M. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm. 2009 Nov-Dec; 6(6):1703-15. PMID: 19736994; PMCID: PMC2941777.
      Citations: 15     Fields:    Translation:AnimalsCells
    134. Kuper KM, Hirsch EB, Tam VH, Houston Infectious Diseases Network. Significant publications on infectious diseases pharmacotherapy in 2008. Am J Health Syst Pharm. 2009 Oct 01; 66(19):1726-34. PMID: 19767379.
      Citations:    Fields:    Translation:Humans
    135. Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2009 Dec; 34(6):570-4. PMID: 19744837.
      Citations: 18     Fields:    Translation:Humans
    136. Tam VH, Ledesma KR, Schilling AN, Lim TP, Yuan Z, Ghose R, Lewis RE. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis. 2009 Aug; 64(4):427-33. PMID: 19631096.
      Citations: 8     Fields:    Translation:AnimalsCells
    137. Singh R, Ledesma KR, Chang KT, Hou JG, Prince RA, Tam VH. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother. 2009 Sep; 64(3):556-62. PMID: 19589810.
      Citations: 8     Fields:    Translation:HumansCells
    138. Tam VH, Ledesma KR, Chang KT, Wang TY, Quinn JP. Killing of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis. 2009 Jun; 64(2):166-71. PMID: 19304437.
      Citations: 10     Fields:    Translation:HumansCells
    139. Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VH. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20. PMID: 19129069.
      Citations: 20     Fields:    Translation:HumansCells
    140. Tam VH, Hou J, Kwa AL, Prince RA. Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother. 2009 Mar; 63(3):627-8; author reply 628-9. PMID: 19022780.
      Citations: 4     Fields:    Translation:Humans
    141. Yeh RF, Kuper KM, Coyle EA, Garey KW, Ikwuagwu JO, Maclayton DO, Mohr JF, Musick WL, Pass SE, Rios E, Tam VH, Houston Infectious Disease Network. Significant publications on infectious diseases pharmacotherapy in 2007. Am J Health Syst Pharm. 2008 Nov 15; 65(22):e72-9. PMID: 18997127.
      Citations:    Fields:    Translation:Humans
    142. Garey KW, Vo QP, Lewis RE, Saengcharoen W, LaRocco MT, Tam VH. Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagn Microbiol Infect Dis. 2009 Jan; 63(1):81-6. PMID: 18990530.
      Citations: 8     Fields:    Translation:Cells
    143. Kwa AL, Low JG, Lim TP, Leow PC, Kurup A, Tam VH. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singap. 2008 Oct; 37(10):826-30. PMID: 19037515.
      Citations: 13     Fields:    Translation:HumansCells
    144. Kwa AL, Tam VH, Falagas ME. Polymyxins: a review of the current status including recent developments. Ann Acad Med Singap. 2008 Oct; 37(10):870-83. PMID: 19037522.
      Citations: 20     Fields:    Translation:HumansCells
    145. Garey KW, Martorell MV, Vo QP, Tam VH. Killing activity of rifampin with piperacillin therapy against adherent cells of Pseumodomas aeruginosa. J Chemother. 2008 Oct; 20(5):652-4. PMID: 19028631.
      Citations: 1     Fields:    Translation:HumansCells
    146. Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother. 2008 Nov; 52(11):3987-93. PMID: 18725438; PMCID: PMC2573104.
      Citations: 17     Fields:    Translation:HumansCells
    147. Lim TP, Ledesma KR, Chang KT, Hou JG, Kwa AL, Nikolaou M, Quinn JP, Prince RA, Tam VH. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2008 Aug; 52(8):2898-904. PMID: 18505848; PMCID: PMC2493134.
      Citations: 13     Fields:    Translation:HumansCells
    148. Yuan Z, Tam VH. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008 May; 17(5):661-8. PMID: 18447592.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    149. Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7. PMID: 18279040.
      Citations: 26     Fields:    Translation:HumansCells
    150. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008 Jul; 62(1):168-71. PMID: 18334494.
      Citations: 41     Fields:    Translation:Humans
    151. Lim TP, Garey KW, Tam VH. Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies. Curr Infect Dis Rep. 2008 Mar; 10(1):9-13. PMID: 18377809.
      Citations:    
    152. Liu X, Tam VH, Hu M. Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. Mol Pharm. 2007 Nov-Dec; 4(6):873-82. PMID: 17927138; PMCID: PMC2597501.
      Citations: 16     Fields:    Translation:HumansCells
    153. Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, Tam VH. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis. 2008 Feb; 60(2):163-7. PMID: 17916420.
      Citations: 28     Fields:    Translation:HumansCells
    154. Tam VH, Schilling AN, Poole K, Nikolaou M. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother. 2007 Dec; 60(6):1302-9. PMID: 17913722.
      Citations: 12     Fields:    Translation:HumansCells
    155. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007 Oct; 5(5):811-21. PMID: 17914915.
      Citations: 41     Fields:    Translation:HumansCells
    156. Tam VH, Chang KT, LaRocco MT, Schilling AN, McCauley SK, Poole K, Garey KW. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14. PMID: 17617302.
      Citations: 14     Fields:    Translation:HumansCells
    157. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis. 2007 Jun 15; 195(12):1818-27. PMID: 17492598.
      Citations: 37     Fields:    Translation:HumansCells
    158. Nikolaou M, Schilling AN, Vo G, Chang KT, Tam VH. Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents. Ann Biomed Eng. 2007 Aug; 35(8):1458-70. PMID: 17431788.
      Citations: 7     Fields:    Translation:Cells
    159. Tam VH, Schilling AN, LaRocco MT, Gentry LO, Lolans K, Quinn JP, Garey KW. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 2007 Apr; 13(4):413-8. PMID: 17359326.
      Citations: 21     Fields:    Translation:HumansCells
    160. Kwa AL, Low JG, Lee E, Kurup A, Chee HL, Tam VH. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Diagn Microbiol Infect Dis. 2007 May; 58(1):99-104. PMID: 17300905.
      Citations: 17     Fields:    Translation:HumansCells
    161. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007 Jan; 29(1):9-25. PMID: 17126534.
      Citations: 32     Fields:    Translation:Humans
    162. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother. 2007 Feb; 51(2):744-7. PMID: 17116679; PMCID: PMC1797751.
      Citations: 61     Fields:    Translation:Cells
    163. Tam VH, Kabbara S, Yeh RF, Leary RH. Impact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob Agents Chemother. 2006 Nov; 50(11):3950-2. PMID: 16954312; PMCID: PMC1635223.
      Citations: 15     Fields:    Translation:Humans
    164. Tam VH, Kabbara S. Comparative performance of different stochastic methods to simulate drug exposure and variability in a population. Diagn Microbiol Infect Dis. 2006 Oct; 56(2):185-8. PMID: 16930922.
      Citations:    Fields:    
    165. Garey KW, Kumar N, Dao T, Tam VH, Gentry LO. Risk factors for postoperative chest wound infections due to gram-negative bacteria in cardiac surgery patients. J Chemother. 2006 Aug; 18(4):402-8. PMID: 17024796.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    166. Tam VH, Kabbara S, Vo G, Schilling AN, Coyle EA. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006 Aug; 50(8):2626-31. PMID: 16870751; PMCID: PMC1538660.
      Citations: 34     Fields:    Translation:HumansCells
    167. Wang SW, Chen J, Jia X, Tam VH, Hu M. Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab Dispos. 2006 Nov; 34(11):1837-48. PMID: 16882763.
      Citations: 31     Fields:    Translation:AnimalsCells
    168. Boucher AN, Tam VH. Mathematical formulation of additivity for antimicrobial agents. Diagn Microbiol Infect Dis. 2006 Aug; 55(4):319-25. PMID: 16626903.
      Citations: 8     Fields:    Translation:Humans
    169. Tam VH, Adams S, LaRocco MT, Gerard LN, Gentry LO, Garey KW. An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm. 2006 Apr 15; 63(8):735-9. PMID: 16595813.
      Citations: 1     Fields:    Translation:HumansCells
    170. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006 Feb; 50(2):469-73. PMID: 16436698; PMCID: PMC1366892.
      Citations: 33     Fields:    Translation:Animals
    171. Lodise TP, Rhoney DH, Tam VH, McKinnon PS, Drusano GL. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006 Mar; 54(3):223-30. PMID: 16423490.
      Citations: 8     Fields:    Translation:Humans
    172. Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006 Jan; 50(1):310-7. PMID: 16377702; PMCID: PMC1346791.
      Citations: 20     Fields:    Translation:AnimalsCells
    173. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Dec; 49(12):4920-7. PMID: 16304153; PMCID: PMC1315965.
      Citations: 70     Fields:    Translation:Cells
    174. Nikolaou M, Tam VH. A new modeling approach to the effect of antimicrobial agents on heterogeneous microbial populations. J Math Biol. 2006 Feb; 52(2):154-82. PMID: 16195922.
      Citations: 12     Fields:    Translation:Cells
    175. Tam VH, Nikolaou M. Mathematical modelling of resistance emergence. J Antimicrob Chemother. 2005 Nov; 56(5):983; author reply 983-4. PMID: 16172104.
      Citations: 1     Fields:    Translation:Humans
    176. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Sep; 49(9):3624-30. PMID: 16127031; PMCID: PMC1195418.
      Citations: 70     Fields:    Translation:Cells
    177. Chen J, Wang S, Jia X, Bajimaya S, Lin H, Tam VH, Hu M. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab Dispos. 2005 Dec; 33(12):1777-84. PMID: 16120792.
      Citations: 29     Fields:    Translation:AnimalsCells
    178. Walker P, Neuhauser MN, Tam VH, Willey JS, Palmer JL, Bruera E, Prince RA. Subcutaneous administration of cefepime. J Pain Symptom Manage. 2005 Aug; 30(2):170-4. PMID: 16125032.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    179. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005 Sep 01; 41(5):754-7. PMID: 16080101.
      Citations: 41     Fields:    Translation:HumansCells
    180. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis. 2005 Aug 01; 192(3):420-8. PMID: 15995955.
      Citations: 42     Fields:    Translation:HumansCells
    181. Tam VH, Schilling AN, Melnick DA, Coyle EA. Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2005 Jun; 52(2):145-51. PMID: 15964503.
      Citations: 11     Fields:    Translation:HumansCells
    182. Tam VH, Schilling AN, Nikolaou M. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother. 2005 May; 55(5):699-706. PMID: 15772138.
      Citations: 45     Fields:    Translation:HumansCells
    183. Tam VH, Schilling AN, Lewis RE, Melnick DA, Boucher AN. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother. 2004 Nov; 48(11):4315-21. PMID: 15504858; PMCID: PMC525451.
      Citations: 13     Fields:    Translation:Cells
    184. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis. 2004 Oct 15; 190(8):1464-71. PMID: 15378439.
      Citations: 87     Fields:    Translation:Animals
    185. Tam VH, Preston SL, Drusano GL. Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Pharmacotherapy. 2003 Dec; 23(12):1545-9. PMID: 14695034.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    186. Tam VH, Preston SL, Drusano GL. Optimal sampling schedule design for populations of patients. Antimicrob Agents Chemother. 2003 Sep; 47(9):2888-91. PMID: 12936990; PMCID: PMC182630.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    187. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003 Jul; 112(2):275-85. PMID: 12865415; PMCID: PMC164285.
      Citations: 109     Fields:    Translation:AnimalsCells
    188. Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003 Jun; 47(6):1853-61. PMID: 12760858; PMCID: PMC155813.
      Citations: 41     Fields:    Translation:HumansCells
    189. Rhoney DH, Tam VH, Parker D, McKinnon PS, Coplin WM. Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003 Mar; 23(3):310-4. PMID: 12627928.
      Citations: 6     Fields:    Translation:Humans
    190. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy. 2003 Mar; 23(3):291-5. PMID: 12627925.
      Citations: 21     Fields:    Translation:HumansCellsPHPublic Health
    191. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002 Sep; 50(3):425-8. PMID: 12205070.
      Citations: 94     Fields:    Translation:HumansCells
    192. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis. 2002 Apr 01; 34(7):922-9. PMID: 11880957.
      Citations: 26     Fields:    Translation:HumansCells
    193. Kwa AL, Tam VH, Rybak MJ. Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review. Pharmacotherapy. 2001 Aug; 21(8):998-1002. PMID: 11718503.
      Citations: 3     Fields:    Translation:HumansCells
    194. McKinnon PS, Tam VH. New antibiotics for infections caused by resistant organisms. Support Care Cancer. 2001 Jan; 9(1):8-10. PMID: 11147147.
      Citations: 1     Fields:    Translation:Humans
    195. Tam VH, Mckinnon PS, Levine DP, Brandel SM, Rybak MJ. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review. Pharmacotherapy. 2000 Sep; 20(9):1116-9. PMID: 10999505.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    196. Tam VH, Moore GE, Triller DM, Briceland LL. Vancomycin peak serum concentration monitoring. J Intraven Nurs. 1999 Nov-Dec; 22(6):336-42. PMID: 10865602.
      Citations:    Fields:    Translation:Humans
    197. Tam VH, Preston SL, Briceland LL. Once-daily aminoglycosides in the treatment of gram-positive endocarditis. Ann Pharmacother. 1999 May; 33(5):600-6. PMID: 10369625.
      Citations: 2     Fields:    Translation:HumansAnimals
    198. Wolfaardt JF, Tam V, Faulkner MG, Prasad N. Mechanical behavior of three maxillofacial prosthetic adhesive systems: a pilot project. J Prosthet Dent. 1992 Dec; 68(6):943-9. PMID: 1494125.
      Citations: 5     Fields:    Translation:Humans
    TAM's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (501)
    Explore
    _
    Co-Authors (19)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _